Therapeutic potential of the novel Bcl‐2/Bcl‐X <sub>L</sub> dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer-Reference-Cited by-同舟云学术

Therapeutic potential of the novel Bcl‐2/Bcl‐X _L dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer

Published:2022-09-06 Issue:11 Volume:61 Page:1031-1042
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Qian Luxi¹²,Vallega Karin A.²,Yao Weilong²³,Wang Dongsheng²,Zhai Yifan⁴,He Xia¹,Sun Shi‐Yong²^ORCID

Affiliation:

1. Department of Radiation Oncology, Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University Nanjing Jiangsu P. R. China

2. Department of Hematology and Medical Oncology Emory University School of Medicine and Winship Cancer Institute Atlanta Georgia USA

3. Department of Gastroenterology, Beijing Friendship Hospital Capital Medical University Beijing P. R. China

4. Ascentage Pharma (Suzhou) Co., Ltd Suzhou Jiangsu P. R. China

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23458

Reference42 articles.

1. Cancer statistics, 2022

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

4. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

5. Overcoming Resistance to Targeted Therapy for Lung Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers;Cancers;2023-10-12